Fintel reports that on October 16, 2023, JP Morgan maintained coverage of Pfizer (NYSE:PFE) with a Neutral recommendation.
Analyst Price Forecast Suggests 35.63% Upside
As of October 5, 2023, the average one-year price target for Pfizer is 45.12. The forecasts range from a low of 32.32 to a high of $78.75. The average price target represents an increase of 35.63% from its latest reported closing price of 33.27.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Pfizer is 79,124MM, an increase of 1.52%. The projected annual non-GAAP EPS is 5.02.
Pfizer Declares $0.41 Dividend
On October 4, 2023 the company declared a regular quarterly dividend of $0.41 per share ($1.64 annualized). Shareholders of record as of November 10, 2023 will receive the payment on December 4, 2023. Previously, the company paid $0.41 per share.
At the current share price of $33.27 / share, the stock's dividend yield is 4.93%.
Looking back five years and taking a sample every week, the average dividend yield has been 3.78%, the lowest has been 2.62%, and the highest has been 5.34%. The standard deviation of yields is 0.52 (n=235).
The current dividend yield is 2.20 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.43. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.08%, demonstrating that it has increased its dividend over time.
What is the Fund Sentiment?
There are 4288 funds or institutions reporting positions in Pfizer. This is a decrease of 97 owner(s) or 2.21% in the last quarter. Average portfolio weight of all funds dedicated to PFE is 0.57%, a decrease of 9.90%. Total shares owned by institutions decreased in the last three months by 1.02% to 4,378,843K shares. 
The put/call ratio of PFE is 0.86, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 233,110K shares representing 4.13% ownership of the company. In it's prior filing, the firm reported owning 218,932K shares, representing an increase of 6.08%. The firm increased its portfolio allocation in PFE by 548.79% over the last quarter.
Capital World Investors holds 199,013K shares representing 3.52% ownership of the company. In it's prior filing, the firm reported owning 231,512K shares, representing a decrease of 16.33%. The firm decreased its portfolio allocation in PFE by 28.09% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 176,053K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 173,954K shares, representing an increase of 1.19%. The firm decreased its portfolio allocation in PFE by 16.05% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 134,410K shares representing 2.38% ownership of the company. In it's prior filing, the firm reported owning 130,981K shares, representing an increase of 2.55%. The firm decreased its portfolio allocation in PFE by 16.44% over the last quarter.
Geode Capital Management holds 112,873K shares representing 2.00% ownership of the company. In it's prior filing, the firm reported owning 109,853K shares, representing an increase of 2.68%. The firm decreased its portfolio allocation in PFE by 16.45% over the last quarter.
Pfizer Background Information
(This description is provided by the company.)
Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
